Press Releases

Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream...

Perrigo Company plc (NYSE: PRGO; TASE) today announced the appointment of independent Directors Geoffrey M. Parker and Theodore R. Samuels to its Board of Directors, further enhancing its...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on December 13, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2016 on Thursday, November 10, 2016 at approximately 6:30 a.m....

Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the...

Perrigo Company plc (NYSE: PRGO; TASE) today acknowledged receipt of a letter from Starboard Value LP, a Perrigo shareholder. Perrigo will review the letter carefully and looks forward to a...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the Morgan Stanley Global Healthcare Conference at 11:05 AM EDT on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium...

Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of...

Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International...

Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m....

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe,...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This...

Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas....

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev®...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on...

Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and...

Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched,...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May...

The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of